AU2002215004A1 - Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening - Google Patents

Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening

Info

Publication number
AU2002215004A1
AU2002215004A1 AU2002215004A AU1500402A AU2002215004A1 AU 2002215004 A1 AU2002215004 A1 AU 2002215004A1 AU 2002215004 A AU2002215004 A AU 2002215004A AU 1500402 A AU1500402 A AU 1500402A AU 2002215004 A1 AU2002215004 A1 AU 2002215004A1
Authority
AU
Australia
Prior art keywords
vpr
hiv
methods
mitochondrial membrane
membrane permeabilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002215004A
Inventor
Anne-Sophie Belzacq
Catherine Brenner-Jan
Lena Edelmann
Johan Hoebeke
Etienne Daniel Francois Jacotot
Guido Kroemer
Bernard Pierre Roques
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Technologie de Compiegne
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Technologie de Compiegne
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Technologie de Compiegne UTC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Technologie de Compiegne, Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Technologie de Compiegne UTC filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2002215004A1 publication Critical patent/AU2002215004A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Abstract

The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
AU2002215004A 2000-09-11 2001-09-11 Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening Abandoned AU2002215004A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23153900P 2000-09-11 2000-09-11
US60/231,539 2000-09-11
US23284100P 2000-09-15 2000-09-15
US60/232,841 2000-09-15
PCT/EP2001/011316 WO2002020570A2 (en) 2000-09-11 2001-09-11 Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening

Publications (1)

Publication Number Publication Date
AU2002215004A1 true AU2002215004A1 (en) 2002-03-22

Family

ID=26925199

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002215004A Abandoned AU2002215004A1 (en) 2000-09-11 2001-09-11 Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening

Country Status (8)

Country Link
US (3) US7056735B2 (en)
EP (1) EP1370572B1 (en)
JP (1) JP2004508385A (en)
AT (1) ATE415414T1 (en)
AU (1) AU2002215004A1 (en)
CA (1) CA2421872A1 (en)
DE (1) DE60136747D1 (en)
WO (1) WO2002020570A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
FR2827866B1 (en) * 2001-07-27 2004-12-10 Pasteur Institut SYNTHETIC OR NATURAL PEPTIDES BINDING PROTEIN PHOSPHATASE 2A, IDENTIFICATION METHOD AND USES
JP2006248978A (en) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
FR2931151A1 (en) * 2008-05-13 2009-11-20 Pharmaleads Soc Par Actions Si NOVEL AMINO ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC USE
US8968336B2 (en) 2011-12-07 2015-03-03 Edwards Lifesciences Corporation Self-cinching surgical clips and delivery system
CN113289001A (en) * 2020-12-24 2021-08-24 上海市闵行区中心医院 Application of Vpr protein N-terminal amino acid polypeptide for regulating and controlling tumor cell apoptosis in preparation of antitumor drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013858A (en) 1996-11-01 2000-01-11 Emory University Mouse lacking heart-muscle adenine nucleotide translocator protein and methods
AU6053898A (en) 1997-08-04 1999-02-22 Burnham Institute, The A cell-free system of mitochondria-dependent apoptosis, and methods of use ther eof
WO1999007845A1 (en) 1997-08-07 1999-02-18 Smithkline Beecham Laboratories Pharmaceutiques Adenosine nucleotide translocator
EP0911341A1 (en) 1997-10-23 1999-04-28 Smithkline Beecham Laboratoires Pharmaceutiques Adenine nucleotide translocator
WO2000026370A2 (en) * 1998-11-03 2000-05-11 Mitokor Adenine nucleotide translocator (ant) fusion proteins and uses thereof
JP4531267B2 (en) 1999-01-22 2010-08-25 ザ バーナム インスティチュート Homing pro-apoptotic conjugates and methods of using homing pro-apoptotic conjugates
US6376211B1 (en) * 1999-07-12 2002-04-23 Xoma Technology Ltd. Agents and methods for inhibiting F1/F0 ATPase

Also Published As

Publication number Publication date
US20040072146A1 (en) 2004-04-15
US7056735B2 (en) 2006-06-06
US20060052285A1 (en) 2006-03-09
CA2421872A1 (en) 2002-03-14
US20020068273A1 (en) 2002-06-06
EP1370572B1 (en) 2008-11-26
DE60136747D1 (en) 2009-01-08
ATE415414T1 (en) 2008-12-15
WO2002020570A2 (en) 2002-03-14
EP1370572A2 (en) 2003-12-17
JP2004508385A (en) 2004-03-18
US7642051B2 (en) 2010-01-05
WO2002020570A3 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
ES2066760T3 (en) ALKINYLAMINE NUCLEOTIDES.
NO20020809L (en) Isomeric bonded pyrrolocarbazoles and isoindolines
DE60030281D1 (en) METHODS OF IMPROVING THE SENSITIVITY AND SPECIFICITY OF SCREENING PROCEDURES FOR CANCER AND CANCER PREPARATIONS
AU9058091A (en) Preparation of nucleic acid samples
ATE217865T1 (en) COMPOUNDS FOR INHIBITING PHOSPHODIESRERASE IV
DE69825066D1 (en) CHANGED PROTEIN KINASES THAT CAN USE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES
TR199901734T2 (en) N�rotrofinlerin ar�t�lmas�.
DK1187632T3 (en) Treatment with anti-ErbB2 antibodies
DE69128077T2 (en) NUCLEIC ACID AMPLIFICATION WITH DNA-DEPENDENT RNS POLYMERASES ACTIVITY OF RNS REPLICASES
DE60231606D1 (en) CIRCULAR PROBLEMS AMPLIFICATION (CPA) OF CIRCULARIZED NUCLEIC ACID MOLECULES
DE60009575D1 (en) DETECTION OF BACTERIA AND BACTERIOPHAGES WITH IMMOBILIZED ENZYME SUBSTRATES
FR2810406B1 (en) NOVEL RARE EARTH CRYPTATES NOT SENSITIVE TO FLUORESCENCE EXTINCTION
DK0539461T3 (en) Method for diagnosing human papillomavirus type 16 using polymerase chain reaction
AU5604900A (en) Phosphorylation assays
AU2002215004A1 (en) Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening
ATE350472T1 (en) JMY, CO-ACTIVATOR FOR P300/CBP, THEREOF-ENCODING NUCLEIC ACID AND USES THEREOF
EP0924296A3 (en) Methods and means for inducing apoptosis by interference in RNA processing
TR200102232T2 (en) The process for isolating pseudomonic acid A from the culture medium containing pseudomonic acid complex.
ATE427960T1 (en) P21 PEPTIDES FOR INHIBITING CDK/CYCLIN COMPLEXES
IL139852A0 (en) Monoclonal antibodies directed against the g3bp protein, and uses
DE60332600D1 (en) SELECTIVE ELUTION OF IMMOBILIZED MULTIPLEXED PRIMER EXTENSION PRODUCTS
DE60228089D1 (en) NUCLEIC ACID AMPLIFICATION WITH DUPLEX INTERMEDIATE PRODUCTS
DK1140933T3 (en) Process for the preparation of N6-substituted deaza-adenosine derivatives
ATE364616T1 (en) NUCLIC ACID MOLECULE, KIT AND USE
CY1109583T1 (en) Mammalian Cytokines, Resistant Reagents